fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2006-01-15
Biotech partner: Nuvelo (USA)
Pharma Partner: Bayer (Germany)
Type of agreement: * commercialization/ distribution
* development
Compound: alfimeprase (an antithrombotic)
Disease area: acute peripheral arterial occlusion, stroke
Development phase: In phase III - launch planned in 2008 in the USA
Nature of the agreement: Nuvelo retains sales rights in the USA and Bayer will sell the drug in the rest of the world
Financial terms of the agreement: - initial payment of $50 million, with total funding of up to $385 million
- 40% of the development cost paid for by Bayer
- royalties for Nuvelo of between 15% and 37.5%


Go back to previous page